Loss-of-function mutations and deletions of EZH2 have also been identified in T cell acute lymphoblastic leukemia (T-ALL) [47]Since EZH2 loss-of-function can drive oncogenesis of certain cancers, caution is required during therapeutic application of EZH2 inhibitors. The gene discussed is EZH2; the disease is T-cell acute lymphoblastic leukemia.